Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416667 | 0.82 | TRPV1 (0.64) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL6826339 | 0.79 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL6822698 | 0.79 | TRPV1 (0.61) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL8021152 | 0.79 | TRPV1 (0.61) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL8002331 | 0.78 | TRPV1 (0.54) | TRPV1KDM4EMEN1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL7637050 | 0.78 | TRPV1 (0.60) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL11722439 | 0.78 | TRPV1 (0.67) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL6825879 | 0.77 | TRPV1 (0.72) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL2676769 | 0.75 | TRPV1 (0.70) | TRPV1KDM4EMEN1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL10893600 | 0.75 | TRPV1 (0.59) | TRPV1KDM4EMEN1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090012-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-6632818-B2 | Piperazine-containing macrocyclic compounds | MERCK & CO., INC. | 2003-10-14 | — | — | US | disclosed |
| US-20030134860-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2003-07-17 | — | — | US | disclosed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1090012-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | TRPV1 4539/4885KDM4E 2184/4885MEN1 783/4885 |
| US-20030134860-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, RCE1 | TRPV1 4267/4885KDM4E 1761/4885MEN1 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.